Theaflavin-3, 3′-digallate inhibits ovarian cancer stem cells via suppressing Wnt/β-Catenin signaling pathway. (November 2018)

• Record Type: Journal Article
• Authors: Pan, Haibo; Kim, Eunhye; Rankin, Gary O.; Rojanasakul, Yon; Tu, Youying; Chen, Yi Charlie
• Is Part Of: Journal of functional foods. Volume 50(2018)
• Page Start: 1
• Page End: 7
• Publication Date: 2018-11
• Subjects: Theaflavin-3 -- 3′-digallate -- Ovarian cancer stem cell -- Anti-proliferation -- ALDH -- β-Catenin; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2018.09.021
• Languages: English
• ISSNs: 1756-4646

Abstract

Graphical abstract: Highlights: TF3 inhibited the proliferation of ovarian CSCs and non-CSCs. TF3 exhibited different inhibitory effect against ovarian CSCs and non-CSCs. TF3 inhibited A2780/CP70 CSCs more strongly than non-CSCs. TF3 inhibited OVCAR3 non-CSCs more strongly than CSCs. TF3 inhibited ovarian CSCs through Wnt/β-catenin signaling pathway. Abstract: Recent evidence indicates that ovarian cancer stem cells (CSCs) are responsible for ovarian cancer recurrence and drug resistance, resulting in the low long-term survival rate of patients with advanced ovarian cancer. We aimed to study the inhibitory effect of theaflavin-3, 3′-digallate (TF3), a black tea polyphenol on ovarian CSCs. Here, we showed that TF3 inhibited the proliferation of A2780/CP70 and OVCAR3 tumorshpere cells by suppressing their cell viability and colony formation capacity. TF3 inhibited the tumorsphere formation capacity of A2780/CP70 and OVCAR3 CSCs in serum-free and non-adherent conditions. TF3 inhibited A2780/CP70 and OVCAR3 CSCs isolated from tumorspheres by decreasing their cell viability and upregulating the protein expression of caspase-3 and -7 in the cells. We also revealed that TF3 inhibited ovarian CSCs through Wnt/β-catenin signaling pathway. Our results suggested that TF3 could inhibit ovarian CSCs and might be a potential agent for eradicating ovarian cancer.